The outlook of companies tied to flagship drugs like Viagra presents a challenging investment picture. While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the expiry in key markets has introduced considerable risk . Investors are now assessing the consequences of rival medications , diminis